Newsletter sample
FDA Warning Monitor Weekly Brief — May 14, 2026
A source-linked newsletter format for compliance consultants, operators, and researchers who want short notes with the public record attached.
Opening note
This week’s public FDA signal is heavy on two practical themes: OTC drug CGMP discipline and recall visibility for devices and food. The short version: product-risk notes are easier to use when the source link is next to the summary.
Three source-backed items
- OTC drug CGMP: Two May warning letters cite finished-pharmaceutical manufacturing and quality-system issues. Read the article.
- Device software and cyber risk: Class I recall entries flagged pacemaker software maintenance and BLE communication vulnerability issues. Read the article.
- Food recall themes: Recent entries show allergen, Listeria, and Salmonella patterns. Read the article.
Reader ask
If you use FDA source documents in client education, follow the LinkedIn page and comment with the category you want tracked next: supplements, compounding, devices, food imports, or claims language.
Boundary: This newsletter summarizes public records for education and research. It is not legal, regulatory, compliance, medical, audit, assurance, certification, approval, tax, or professional advice.